278 related articles for article (PubMed ID: 26456706)
1. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Came N; Nguyen V; Westerman D; Harrison S
Br J Haematol; 2016 Jun; 173(6):947-9. PubMed ID: 26456706
[No Abstract] [Full Text] [Related]
2. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
3. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
4. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
5. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
[TBL] [Abstract][Full Text] [Related]
11. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
12. Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma.
Royston DJ; Gao Q; Nguyen N; Maslak P; Dogan A; Roshal M
Am J Clin Pathol; 2016 Jul; 146(1):41-9. PubMed ID: 27402608
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease.
Deptala A; Mayer SP
Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
[No Abstract] [Full Text] [Related]
14. Plasma cell myeloma with unusual morphology--a series of 6 cases.
Gupta R; Hussain N; Rahman K; Nityanand S
Eur J Haematol; 2014 Aug; 93(2):165-70. PubMed ID: 24628605
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE
Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630
[No Abstract] [Full Text] [Related]
16. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
Jiang XY; Luider J; Shameli A
Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
[TBL] [Abstract][Full Text] [Related]
17. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
19. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
